Lineage Cell Therapeutics (LCTX) Long-Term Investments (2016 - 2019)
Lineage Cell Therapeutics (LCTX) posted quarterly Long-Term Investments of $19.0 million for Q4 2019, up 40.92% year-over-year from $13.5 million in Q4 2018, and up 7.34% quarter-over-quarter from $17.7 million in Q3 2019.
Lineage Cell Therapeutics (LCTX) Long-Term Investments (2016 - 2019) Analysis & Trends
Lineage Cell Therapeutics' Long-Term Investments history runs 4 years deep, the most recent figure standing at $19.0 million for Q4 2019.
- In Q4 2019, Long-Term Investments rose 40.92% year-over-year to $19.0 million; the TTM figure through Dec 2019 stood at $19.0 million (up 40.92% YoY), while the FY2019 annual figure was $19.0 million, up 40.92% from the prior year.
- Long-Term Investments for Q4 2019 stood at $19.0 million, up from $17.7 million in the prior quarter.
- The five-year high for Long-Term Investments was $110.8 million in Q3 2017, with the low at $3.5 million in Q3 2016.
- The 4-year median for Long-Term Investments is $33.7 million (2018), against an average of $45.2 million.
- The sharpest annual moves came in 2017 and 2018: Long-Term Investments soared 3082.08% in 2017, then sank 80.23% in 2018.
- Lineage Cell Therapeutics' Long-Term Investments stood at $100.0 million in 2016, then tumbled by 31.8% to $68.2 million in 2017, then tumbled by 80.23% to $13.5 million in 2018, then jumped by 40.92% to $19.0 million in 2019.
- Business Quant data shows LCTX's Long-Term Investments at $19.0 million in Q4 2019, $17.7 million in Q3 2019, and $36.5 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 19.00 Mn |
| Sep 30, 2019 | 17.70 Mn |
| Jun 30, 2019 | 36.54 Mn |
| Mar 31, 2019 | 58.00 Mn |
| Dec 31, 2018 | 13.48 Mn |
| Sep 30, 2018 | 28.27 Mn |
| Jun 30, 2018 | 29.40 Mn |
| Mar 31, 2018 | 30.82 Mn |
| Dec 31, 2017 | 68.20 Mn |
| Sep 30, 2017 | 110.80 Mn |
| Jun 30, 2017 | 77.20 Mn |
| Mar 31, 2017 | 73.94 Mn |
| Dec 31, 2016 | 100.00 Mn |
| Sep 30, 2016 | 3.48 Mn |
| Jun 30, 2016 | 52.19 Mn |
| Mar 31, 2016 | 4.44 Mn |